The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 23 March 2026•Updated 24 March 2026•

1 min read

Apogee Therapeutics Surges 14% on Potential Rival to Regeneron’s Blockbuster Eczema Drug

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Apogee Therapeutics shares rose 14% following positive reports regarding its potential eczema drug candidate.

2 months ago

Version History

4 additional sources confirmed this story

Version 12 months ago

What changed: Added the specific drug name (zumilokibart), clinical efficacy percentages (75-85% EASI-75), detailed the extended dosing intervals (Q3M/Q6M), and included the multi-year clinical trial roadmap.

Shares of Apogee Therapeutics surged 14% following the release of specific clinical data for its eczema treatment candidate, now identified as zumilokibart. The drug demonstrated impressive efficacy, achieving an EASI-75 response rate of 75-85% among responders by Week 16. A key competitive advantage is the extended dosing schedule, with intervals of every 3 or 6 months (Q3M and Q6M), positioning it as a strong rival to Regeneron’s Dupixent. The company has established a clear clinical roadmap, with Phase 2 data expected in Q2 2026 and the initiation of Phase 3 trials in the second half of 2026. Market analysts view these specific efficacy results and the long-term catalyst timeline as a "best-case scenario" for the firm's pipeline. This update reinforces investor confidence in Apogee’s potential to disrupt the dermatology market through superior dosing convenience and clinical performance.